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Abstract
: Fenofibrate, an agonist of PPAR-alpha, in doses above 25 µM, inhibits proliferation and induces
apoptosis in Ishikawa endometrial cancer cells. We show that these effects are potentiated by
retinoic acid, an agonist of the retinoid-X-receptor. DNA content analysis shows that G1/S phase
progression through the cell cycle is inhibited. Independent Component Analysis of gene
microarray experiments demonstrated downregulation of Cyclin D1 (CCND1) and associated
changes in cell cycle gene expression. Expression of PPAR-alpha mRNA was reduced by >75% using
RNA-interference but this resulted in only minor changes in biological effects. A nude mouse model
of endometrial carcinoma was used to investigate the effect of fenofibrate in vivo but failed to show
consistent inhibition of tumour growth.
Conclusion: The combination of fenofibrate and retinoic acid is a potent inhibitor of Ishikawa
endometrial cancer cell growth in vitro.
Introduction
Endometrial cancer is the most prevalent gynaecological
cancer in the UK, and represents the third commonest
cancer affecting women in the Western World [1]. By con-
trast, the incidence in the non-Western world is approxi-
mately ten-fold lower [2]. The excellent prognosis of early
stage endometrial cancers belies the impact of the disease
on mortality, being of similar magnitude to that of cervi-
cal cancer [2]. Indeed, the long-term survival of advanced
stage endometrial cancer, at approximately 10%, is simi-
lar to that of ovarian cancer.
Established risk factors for sporadic endometrial cancer
mainly involve hormonal factors, with the unopposed
estrogen hypothesis believed to be the central pathoge-
netic mechanism [3,4]. Although this theory is strongly
supported, it does not satisfactorily account for all the risk
factors associated with endometrial cancer risk. Obesity is
a significant independent risk factor, with relative risks in
the 2–10 range [5,6]. The mechanism for this has not yet
been elucidated but postulates include the collateral
involvement of estrogen and insulin-like growth factor
(IGF) receptor pathways [5,7]. Improving understanding
of the carcinogenesis of endometrial cancer is essential in
the development of targeted therapy.
The potential of gene array methods and systems biology
has been exploited in recent years for the investigation of
a number of tumour types [8,9]. The aim of the new biol-
ogy is to provide a global overview of carcinoma at the
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data. Although oncology has received a great deal of atten-
tion from computational biology, a limited number of
gene array studies have been applied solely to endome-
trial cancer [10-12].
Using gene array methods within a computational biol-
ogy environment, we have previously demonstrated that
lipid metabolism is likely to play an important role in
endometrial carcinogenesis [12,13]. Consequentially, we
identified fenofibrate, a ligand of the peroxisome prolifer-
ator-activated receptor alpha (PPARα), as a potential ther-
apeutic agent in endometrial cancer [12]. PPARs comprise
a group of transcription factors belonging to the nuclear
hormone receptor subfamily and consist of subtypes α, γ
and β/δ [14]. Their main actions regulate the metabolism
of fatty acids and are therefore closely involved with pros-
tanoid pathways [14]. Furthermore, receptor-mediated
transcription is dependent upon heterodimerisation with
the retinoid-X receptors (RXRs). Following activation by
their ligands (eg fenofibrate and fatty acids in the case of
PPARα) and heterodimerization with RXR, PPARs bind to
the peroxisome-proliferator response element (PPRE) in
the promoter of their target genes and activate their tran-
scription [14]. PPREs are most commonly found in genes
that are involved in lipid metabolism and energy homeos-
tasis, including lipid storage or catabolism (β-oxidation
and ω-oxidation), fatty-acid transport, uptake and intrac-
ellular binding. In recent years there has been interest and
some success in the use of retinoids, synthetic ligands of
the RXR, in the treatment of hormonally derived cancers
such as those of the breast and endometrium [15,16].
Our previous work demonstrated upregulation of PPARα
transcript in association with downregulation of its het-
erodimerisation partner RXRβ [12,13] in endometrial
cancer. We also showed that the PPARα agonist fenofi-
brate, in doses above 25 µM, inhibits Ishikawa and ECC-
1 endometrial cancer cell growth in vitro, in association
with increased apoptosis and PPARα receptor activation
[12]. In this study, attention was focussed on the Ishikawa
cell line in view of its endometrioid-like characteristics,
estrogen receptor positivity [17] and suitability for
xenografting [18].
Having identified PPARα as a potential therapeutic target
in endometrial cancer, the aim of this study was to further
investigate the biological effects of fenofibrate, from a
molecular to a cellular level and finally to an animal
model. We further aimed to investigate whether targeting
the PPARα receptor using retinoid-X-receptor ligands
would increase the growth-inhibitory effects of this agent.
Finally, a systems biology approach was used to help
understand the mode of action of fenofibrate by identify-
ing the global transcription changes induced in the treat-
ment of endometrial cancer in vitro.
Materials and methods
In vitro studies
Cell culture & proliferation assays
Ishikawa cells were obtained from the European Collec-
tion of Cell Cultures (Cat. No. 99040201) [19] and were
grown in DMEM/F-12 Ham medium (Cat. No. D6421,
Sigma-Aldrich, UK) supplemented with L-glutamine and
10% fetal calf serum in 96-well plates (proliferation
assays), 6-well plates (FACS analysis, luciferase reporter
assays) or cell culture flasks (RNA extraction, tumour
explant preparation). Cells were cultured at 37°C and
5%CO2 with varying doses of fenofibrate (Cat. No.
F6020), 9-cis retinoic acid (9-cRA) (Cat. No. R4643) or
all-trans retinoic acid (ATRA) (Cat. No. R6265, all Sigma-
Aldrich, UK) dissolved in DMSO (Sigma-Aldrich). Con-
trol cells were treated with DMSO and the concentration
of DMSO was kept the same throughout each experiment,
to a maximum of 1% v/v. A minimum of five replicates
per dose was performed for automated assays (BrdU and
MTS) and all other cell culture experiments were per-
formed independently in duplicate or triplicate. Cell pro-
liferation was measured by the uptake of 5-bromo-2'-
deoxyuridine (BrdU) using the BrdU Labelling and Detec-
tion Kit (Cat. No. 1444611, Roche, UK) according to the
manufacturer's instructions. Relative cell abundance was
measured either by cell counting, or using an MTS assay
(CellTiter 96 Aqueous Cell Proliferation Assay, Cat. No.
TB169, Promega, UK). Absorbance values for each well
were measured using a microtiter plate reader (Anthos
Labtech Instruments, Salzburg, Austria)
FACS analysis
All FACS analysis was performed on a FACSCalibur ana-
lyser (Becton Dickinson, USA). Computational analysis
was performed using FCSPress software for Macintosh
[20]. Gating parameters were based on untreated cells in
each experiment, to exclude subcellular fragments and
conglomerate cells.
Apoptosis analysis
Cells in 6-well plates at approximately 80% confluence
were washed in PBS, and the medium replaced with
medium containing DMSO (control) or drug in DMSO
solution to a maximum of 1% v/v DMSO. After 3 hours'
exposure, the cells were harvested by trypsinisation, spun,
and resuspended in 500 µl buffer (containing per ml of
serum-free medium: 4 µl Propidium Iodide (Cat. No.
P3566, Invitrogen, USA), 3.5 µl Annexin-V FITC (Cat. No.
A13199, Invitrogen, USA), 10 µl 0.1 M Calcium chloride).
Cells were transported on ice and FACS analysis was per-
formed within one hour.Page 2 of 14
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Cells were similarly treated with drug solution for 12
hours, and harvested as above. Approximately 106 cells
were fixed in 0.3 ml of PBS and 0.7 ml of ice cold 70%
EtOH at 4°C for 1 hr. After fixation, the cells were resus-
pended in 0.25 ml of PBS containing 12.5 µl of PI and
6.25 µl RNase A (20 mg/ml, SIGMA, UK). Cells were incu-
bated at 37°C for 15 minutes prior to FACS analysis.
Cell counting
Cell counting was independently verified using FACS
analysis. Samples harvested by trypsinisation were fixed in
ethanol as above. 20 µl of a 1:1000 aqueous solution of
Fluoresbrite plain YG 2 µm beads (Cat. No. 18338, Poly-
sciences Inc, Germany) was added to 1 ml of cells resus-
pended in PBS containing 10 µl Propidium Iodide
solution, giving a final bead concentration of 5.68 × 105/
ml. Cell concentration was then calculated as: (Cell
count) × (Bead Count)-1 × (5.68 × 105)
RNA interference
RNAi was performed through a lipid-based transfection
method, with either PPARα-RNAi (Cat. No. M-003434-
00) or Control-RNAi (Cat. No. D-001206-13), using
SmartPool reagents (Dharmacon, Lafayette CO, USA)
according to the manufacturers' instructions. Cells were
harvested at confluence from a 75 cm2 culture flask, and
plated at approximately 2 × 106 cells per plate into 6 well
plates with 2 ml/well of medium as described. For trans-
fection, 5 µl/well of 20 µM RNAi (control or PPAR), 4 µl/
well of lipofectamine 2000 (Cat. No. 18324-111, Invitro-
gen, UK) and 100 µl/well of serum-free medium were
incubated at room temperature. 100 µl/well of transfec-
tion mixture was then added to each well for overnight
transfection, giving a transfection rate ≥30%, as measured
by beta-galactosidase staining. The medium was replaced
with fresh medium and cells grown to confluence. Cells
were then harvested and pooled in each group (control
RNAi/PPAR RNAi) before replating to 6-well plates. Cells
later harvested for RT-PCR analysis were plated from the
same batches. For cell counting, cells were allowed to
grow in drug-containing media for 48 hours, then har-
vested. For FACS analysis (apoptosis assays), drug-based
media was added to cells for 2 hours before harvesting.
Microarray studies
RNA preparation
Cells in the logarithmic growth phase were plated into 75
cm2 culture flasks containing culture medium as
described, containing DMSO or fenofibrate solution (in
DMSO at 10 µM and 100 µM) as required. Five replicate
cultures were grown at each drug dose. Cells were cultured
for 48 hours, and then harvested by cell scraper using 1 ml
Trizol reagent (Cat. No. 15596-026, Invitrogen, UK) per
flask, and stored overnight at -70°C. RNA was then pre-
cipitated and resuspended using an isopropanol precipa-
tion method [21]. cDNA was generated using random
hexamer primers as described previously [22].
Sequencing
cDNA generated as above was used as template DNA for
35 cycles of PCR using the following conditions: 95°C
(30s), 57°C (30s), 72°C (60s). To facilitate sequencing of
large fragments, 2 overlapping fragments were amplified,
covering the entire coding sequence, using the following
primers:
Forward: 5'-GGCACAACCAGCACCATCT-3'
Reverse: 5'-CTCCACAGCAAATGATAGCAGC-3'
(Amplicon length 1185 bp, position 191-1375)
Forward: 5'-GCCAGTAACAATCCACCTTTT-3'
Reverse: 5'-AAGGTGTGGCTGATCTGAAGG-3'
(Amplicon length 735 bp, position 913-1647)
The PCR products were then subjected to electrophoresis
on a 2% agarose gel. Bands corresponding to the above
amplicons were then extracted from the gel using the
Qiaquick kit according to the manufacturer's instructions
(Cat. No. 28704, Qiagen, UK). This product was then
used as template for a further 25 cycles of PCR, from
which the relevant bands were again extracted and
sequenced using the above primers on an ABI Prism 310
genetic analyzer (Applied Biosystems, UK). Sequence
analysis and comparison was performed using DNAstar
software (DNAstar Inc, USA).
Preparation of cDNA for microarray hybridisation
Following precipitation from Trizol, RNA was re-extracted
using RNAeasy mini-columns (Cat. No. 74106, Qiagen,
UK) and assayed for purity and concentration using spec-
trophotometry and an Agilent 2100 Bioanalyzer (Agilent,
USA). Glass microarrays sourced from within the Univer-
sity of Cambridge Department of Pathology were printed
on 2 slides and comprised over 10000 clones from various
sources as previously described [22,23]. Confirmation of
the array's performance had been conducted by in-house
analysis of reproducibility [24], in addition to its use in
prior validated experiments [23]. Further quality control
of the arrays in this experiment was ensured by reproduc-
ibility analysis of the array data generated from the pooled
DNA samples (see additional file 1). cDNA synthesis and
labelling for hybridization was carried out as previously
described with minor modifications [25]. 1 µg total RNA
was used to synthesise double-strand cDNA (ds-cDNA)
using the SMART PCR cDNA synthesis kit (Clontech, UK),Page 3 of 14
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cycles of PCR.
Spotted oligonucleotide microarray hybridisation and scanning
The ds-cDNA was labelled by Cy3-deoxyuridine triphos-
phate or Cy5- deoxyuridine triphosphate (Amersham-
Pharmacia, UK) using the Bioprime DNA labelling kit
(Cat. No. 18094-011, Invitrogen, UK) with random hex-
amers. To counter the effect of dye bias, a reference cDNA
consisting of amplified cDNA pooled from the five con-
trol-treated samples was labelled with Cy3. Each of the 15
sample cDNAs were labelled with Cy5. Paired samples
(Pooled-Cy3 + Sample-Cy5) were purified using Autoseq
G50 columns (Amersham, UK), mixed with 5 µg/ml
Human Cot-1 DNA (Cat. No. 15279-011, Invitrogen,
UK), 1 µg/ml Poly-dA (Amersham-Pharmacia, UK).
Labelled targets were resuspended in 50 µl of hybridisa-
tion buffer (40% formamide, 5× SSC, 5× Denhardt's solu-
tion, 1 mM sodium pyrophosphate, 50 mM Tris pH 7.4,
0.1% SDS), denatured at 95°C for 5 min, incubated at
50°C for 5 min and then centrifuged at 8000 rpm for 5
min before being applied to the cover-slipped array.
Hybridisations were performed at 50°C in a humidified
environment for 16 h. Following hybridisation, slides
were washed twice in 2× SSC for 10 min, twice in 0.1×
SSC/0.1% SDS for 5 min and finally twice in 0.1× SSC for
5 min; all washes were performed at room temperature.
After washing, slides were dried by centrifugation at 1000
rpm for 2 min, and then scanned using a Genepix 4100
microarray scanner (Axon Instruments, Foster City, CA).
The scanned images were processed by using GenePix Pro
4.1 software (Axon).
Analysis of gene array data
Raw Cy3- and Cy5- channel data extracted using Imagene
were normalized against a reference array using a LOESS-
based algorithm with a span of 0.4 as previously described
[13]. Empty spots and known housekeepers were
removed from the data. Independent Component Analy-
sis [26] was performed on the remaining data set. Compo-
nents extracted were then compared against the array
grouping using ANOVA in the R-statistical environment,
to identify components related to drug dosage, where p <
0.01. Significant genes relating to high-dose fenofibrate
were those with the top 1% of component loadings in the
relevant component. Analysis of gene ontology (GO) clas-
sification was performed as previously described [13]
Quantitative Real-Time PCR (Taqman)
RNA samples analysed by RT-PCR were the same as those
used for microarray analysis. Total RNA (2 µg) was incu-
bated with random hexamer primers at 70°C and reverse-
transcribed at 42°C using Super Reverse Transcriptase (HT
Biotechnology Ltd, Cambridge, UK). 0.6 µl of template
DNA was amplified using PCR MasterMix (Cat. No. AB-
1142, ABgene, UK). All RT-PCR experiments were per-
formed in an ABI Prism 7700 Sequence Detector (Applied
Biosystems) in triplicate. Results for gene abundance in
each sample were normalised to abundance of 18S RNA
when appropriate. Normalised log-transformed transcript
levels were compared across samples using one-way
ANOVA and Student's t-tests.
(i) PPARα
Due to the low abundance of the PPARα transcript, 20
cycles of PCR (see below for conditions) were performed
prior to the quantitative PCR cycles. The following prim-
ers were used to amplify a 553 bp region of PPARα which
was subsequently amplified with Taqman reagents.
Forward: 5'-AGGGCCCTGTCTGCTCTGTG-3'
Reverse: 5'-CGGGTGGACTCCGTAATGATAG-3'
PCR product from this round of PCR was used as the tem-
plate for subsequent quantitative PCR. Primer/probe
sequences used for RT-PCR were:
Forward primer: 5'-GACGTGCTTCCTGCTTCATAGA-3'
Reverse primer: 5'-CACCATCGCGACCAGATG-3'
Probe: 5'-6FAM-TGGAGCTCGGCGCACAACCA-TAMRA-
3'
(ii) Verfication of gene arrays
RT-PCR for three genes selected from microarray analysis
was performed using the assays-on-demand primers
below according to the manufacturers instructions
(Applied Biosystems, USA).
(a) Cyclin D1 (CCND1) (Cat. No. Hs00277039_m1)
(b) Methionine adenosyltransferase II alpha (MAT2A)
(Cat. No. Hs00428515_g1)
(c) Phosphoenolpyruvate carboxykinase 2 (PCK2) (Cat.
No. Hs00356436_m1)
Animal studies
All animal care and experimental protocols were
approved by the animal ethics committee of the Univer-
sity of Cambridge and the Home Office of the United
Kingdom government. 6-week old female cd-1 nude mice
(Charles River Inc) were ovariectomised and implanted in
the flank with one-half of a 1.5 mg 60-day release estra-
diol pellet (Cat. No. SE-121, Innovative Research of Amer-
ica, USA). After one week, mice that were to receive
retinoic acid were implanted with a further pellet in the
neck containing 5 mg ATRA (Cat. No. V-111, InnovativePage 4 of 14
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containing 0.1% or 0.25% fenofibrate (constituted by Lil-
lico Biotechnology, Surrey, UK) or the same diet without
fenofibrate. Approximately 1 million Ishikawa cells in
100 µl Matrigel (Cat. No. 35-6234, BD Biosciences, UK)
were injected subdermally into the left flank, raising a
bleb. Mice were checked daily and weighed twice-weekly
to ensure good health. At the end of the experiment the
mice were culled, the tumours were excised from sur-
rounding tissue and weighed. Immunohistochemistry for
PPARα was performed on selected harvested tumour sam-
ples as previously described [12]
Statistics
All statistical analyses were performed under the R statis-
tical environment [27]. Where appropriate, Student's t-
test, Wilcoxon Rank-Sum test or one-way ANOVA was
used for comparisons as indicated. Methods particular to
gene array analysis are described above.
Results
Growth inhibitory effect of fenofibrate is precipitated by 
retinoic acid
Treatment of Ishikawa cells with 50 µM fenofibrate over
48 hours significantly reduced cell growth (27%, p <
0.05). Although treatment with 10 µM all-trans retinoic
acid (ATRA) had no significant effect on cell growth, com-
bined treatment with 50 µM fenofibrate caused a greater
reduction in cell number than produced by fenofibrate
alone (49%, p < 0.05). Treatment with high dose ATRA
combined with fenofibrate caused >90% reduction in cell
number (p < 0.05) (figure 1a). In addition, a dose-
response was demonstrated when 10, 30 or 50 µM fenof-
ibrate was combined with 30 µM ATRA (figure 1b). Simi-
lar effects were seen with retinoic acid, where no
inhibition of cell growth was detected below 50 µM in the
absence of fenofibrate (data not shown). BrdU assays
Top – DNA content analysisFigure 2
Top – DNA content analysis. The bars represent the ratio of 
cells in G1:G2M phase of the cell cycle after 12 hours of 
treatment with drug (RA+ = ATRA 10 µM. RA++ = ATRA 
30 µM, FN+ = Fenofibrate 30 µM, FN++ = Fenofibrate 100 
µM). Bottom – Apoptosis by FACS analysis using Annexin-
FITC staining. Cells were treated for 3 hours. FN = fenofi-
brate, RG = rosiglitazone, St = staurosporine, a potent apop-
togen.
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Effect of fenofibrate and retinoic acid (48 hours exposure) on 
endometrial cancer cell growth, using cell counting (Top) and 
MTS assay (Bottom).
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fenofibrate but failed to show a similar effect with high
dose rosiglitazone, a PPARγ agonist. Other PPAR agonists
and antagonists were tried but failed to show a significant
effect in the doses used (data not shown)
Fenofibrate induces cell cycle arrest and apoptosis in 
Ishikawa cells
The proportion of cells in G1 and G2M phases of the cell
cycle were measured by FACS analysis after 12-hour expo-
sure to fenofibrate. Application of 50 µM or 100 µM
fenofibrate increased the ratio of cells in G1 phase to G2M
phase of the cell cycle (data not shown, p < 0.05, Student's
t-test). Treatment of ISK cells with 100 µM fenofibrate
combined with 30 µM ATRA, however, had a greater effect
on cell cycle progression than either drug alone (figure
2a). The effect of fenofibrate and retinoic acid on apotosis
was also measured by FACS analysis, and similarly dem-
onstrated an increase in apotosis induction when the
drugs were combined (figure 2b).
Although our previous results had suggested a direct effect
of fenofibrate on the PPARα receptor, experiments con-
ducted using RNAi for PPARα failed to show a dramatic
reduction in fenofibrate effect. This was despite achieving
consistent downregulation of >75% in PPARα expression
as measured by RT-PCR (Figure 3a). The effect of ATRA
combined with fenofibrate on cell growth was similar in
the presence or absence of PPARα RNAi (figure 3b). How-
ever, the total viable cell number in the PPARα- trans-
fected control-treated cells was approximately 40% lower
than the control RNAi transfected cells. After correcting
for this difference, the effect of 75 µM fenofibrate (48
hours treatment) on cell growth inhibition was less in the
RNAi transfected cells (p = 0.05, t-test) (figure 3b).
Genes affected by fenofibrate in Ishikawa cells
Using Independent Component analysis (ICA), a compo-
nent relating to treatment with high-dose fenofibrate (100
µM) was identified in both gene array experiments (slide
1 & slide 2) (p < 0.01 after correction for multiple testing.
Other significant components identified from ICA related
to batch effects (hybridisation date, RNA preparation
date, hybridisation batch) (p < 0.01, ANOVA). Batch
effects were so strong that the "dose" component was only
the 9th largest of 30 components. No component could be
identified relating to "low dose" (10 µM) fenofibrate
treatment.
Significant genes from the identified component were
selected as those with absolute component loading values
greater than 3 standard deviations, treating positive and
negative values separately. This was an arbitrary value pro-
viding a reasonable number of genes all of which had
component loadings outside the inflexion of the plotted
Top – mRNA expression as quantified using Taqman RT-PCR following RNAi for PPARα using RNAi concentration shownFigure 3
Top – mRNA expression as quantified using Taqman RT-PCR 
following RNAi for PPARα using RNAi concentration shown. 
Middle – Cell growth following RNAi and treatment with 
fenofibrate (FN) and ATRA (RA) for 48 hours. Cell numbers 
were corrected to adjust for the reduced cell growth follow-
ing PPARα RNAi compared to control RNAi. Bottom – 
Apoptosis measured by FACS analysis using Annexin-FITC 
staining following RNAi and treatment with fenofibrate and 
retinoic acid for 3 hours.
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Genes identified as differentially expressed after treatment with high-dose (100 µM) fenofibrateFigure 4
Genes identified as differentially expressed after treatment with high-dose (100 µM) fenofibrate. The plots show upregulation 
(red) and downregulation (green) of expression compared to DMSO control-treated cells. Cells were treated with 10 µM 
("low dose") or 100 µM ("high dose") fenofibrate for 48 hours. Left – Normalised uncorrected data. Right – Data corrected 
using ICA-based filtering and removal of artefactual components. The data is improved but reveals an aberrant sample in the 
high-dose group (the first).
Molecular Cancer 2006, 5:13 http://www.molecular-cancer.com/content/5/1/13curve (see additional file 1). At this threshold, 425 gene
spots representing 213 annotated unique genes from Slide
1 were identified as differentially expressed following
treatment with high dose fenofibrate. A similar number of
differentially expressed genes were additionally identified
from the second microarray experiment (using Slide 2
which contained a greater number of non-anottated
clones). A subset of genes from the Slide 1 geneset is dis-
played as an expression plot in figure 4a.
Three genes were chosen for RT-PCR validation of the
gene array (figure 5): Cyclin D1 (CCND1), Phosphoenol
pyruvate carboxykinase 2 (PCK2) and Methionine Adeno-
syltransferase 2A. These genes were chosen due to a com-
bination of their loading value in the component of
interest (suggesting a significant effect) as well as their
biological interest. Both CCND1 and MAT2A were down-
regulated following treatment with fenofibrate 100 µM.
RT-PCR analysis confirmed downregulation in gene
expression (CCND1 3.2-fold, MAT2A 5.6-fold, p < 0.05).
RT-PCR analysis confirmed a small increase in PCK2
expression (1.3-fold, p = NS) in the treated cells but this
was less than that seen with the array data (figure 5c).
Gene Ontology analysis revealed a number of functional
groups which were significantly over-represented in the
transcripts identified as altered by fenofibrate. A func-
tional group was considered to be over-represented in the
gene list when the number of gene spots belonging to that
group was higher than expected from the distribution of
genes on the array (chi-squared test). The following func-
tional groups of interest were identified as being over-rep-
resented by the genes altered with fenofibrate treatment
(see table 1): nucleotide binding (GO:0000166), MAP
kinase-related (GO:0017017, GO:0000188,
GO:0000185), cell growth (GO:0016049, GO:0008283),
cyclin-dependent protein kinase inhibitor
(GO:0004861), insulin-like growth factor binding
(GO:0005520), platelet-derived growth factor receptor
ligand (GO:0005161), metalloprotease inhibitor
(GO:0008191) and cell cycle arrest (GO:0007050). The
full table of GO classifications, by significance level, is
provided in additional file 2.
Effect of fenofibrate on tumour growth in vivo
Two separate in vivo experiments were performed (figure
6). In the first, mice were allocated to each of three groups
– (1) normal diet (N = 6), (2) low-dose fenofibrate
(0.1%) (N = 4), (3) high-dose fenofibrate (0.25%) (N =
6). The median tumour weights at 21 days in the three
groups were (1) 684 g (2) 1280 g (3) 439 g. There was a
trend towards lower tumour weights in the high-dose-
treated group compared to those receiving normal diet (p
= 0.046, Mann-Whitney test, one-sided). Surprisingly,
however, the group fed low-dose fenofibrate demon-
Comparison between array data and gene expression (as measured using Taqman RT-PCR)Figure 5
Comparison between array data and gene expression (as 
measured using Taqman RT-PCR). The "532 control" column 
represents the green-channel array data from the pooled 
cDNA (from DMSO-treated control samples) and is used as 
an internal control. Three genes were chosen for verification 
of the array: top – Cyclin D1, middle – Methionine Adenosyl-
transferase 2-alpha, bottom – Phosphoenolpyruvate carbox-
ykinase 2.
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Whitney test).
In the second experiment, 8 mice were allocated to each
of four groups, to receive (1) normal diet, (2) high-dose
fenofibrate (0.25%), (3) ATRA, (4) ATRA + fenofibrate.
All mice treated with ATRA were culled at day 14 due to
weight loss (>10% starting weight) and the majority dis-
played a local reaction to the ATRA pellet. The remaining
mice were culled at day 28. There were no significant dif-
ferences between the tumour weights in the groups com-
pared (fenofibrate vs normal diet; ATRA vs ATRA +
fenofibrate) (Mann-Whitney test, p > 0.05)
Discussion
To our knowledge, we are the only group to have pub-
lished on the effects of fenofibrate in endometrial cancer
in vitro [12]. Our previous data demonstrated a moderate
inhibitory effect of fenofibrate on endometrial cancer cell
growth but with limited understanding of the mechanism
of this effect. This study significantly expands on this
knowledge.
We have confirmed, using additional methods, that
Ishikawa endometrial cancer cell growth is inhibited by
fenofibrate. We have also confirmed, by using FACS anal-
ysis, that fenofibrate increases apoptosis in ISK cells in
Table 1: Selected genes derived from ICA & GO analysis of gene array experiments. Genes are combined into ontologies. Average 
Fold Changes are calculated from normalised values over the number of spots shown for each gene. As can be seen, not all genes are 
differentially expressed according to t-test p-values. Genes are instead selected based on their ICA loading (see discussion)
GO Description Gene 
symbol
Description No of spots Ave FC Ave ttest p
activation of MAPKKK (GO:0000185) GADD45B growth arrest and DNA-damage-inducible, beta 2 2.6 0.090
cell cycle arrest (GO:0007050) EIF4G2 eukaryotic translation initiation factor 4 gamma, 2 2 1.2 0.249
GADD45A growth arrest and DNA-damage-inducible, alpha 2 5.1 0.003
PPP1R15A protein phosphatase 1, regulatory (inhibitor) 
subunit 15A
2 1.4 0.085
PR48 protein phosphatase 2A 48 kDa regulatory subunit 1 -1.1 0.427
SESN3 sestrin 3 2 -1.3 0.161
TP53 tumor protein p53 (Li-Fraumeni syndrome) 4 1.7 0.036
cell death (GO:0008219) EIF4G2 eukaryotic translation initiation factor 4 gamma, 2 2 1.2 0.249
EMP3 epithelial membrane protein 3 2 1.7 0.111
cell growth (GO:0016049) P8 p8 protein (candidate of metastasis 1) 2 3.1 0.005
SLC3A2 solute carrier family 3 (activators of dibasic and 
neutral amino acid transport), member 2
4 2.0 0.012
cell proliferation (GO:0008283) EGFR epidermal growth factor receptor (erythroblastic 
leukemia viral (v-erb-b) oncogene homolog, avian)
2 2.2 0.009
FTH1 ferritin, heavy polypeptide 1 1 1.2 0.301
IGFBP4 insulin-like growth factor binding protein 4 2 1.8 0.002
OSMR oncostatin M receptor 2 1.7 0.088
PDGFA platelet-derived growth factor alpha polypeptide 2 1.5 0.032
PDGFB platelet-derived growth factor beta polypeptide 
(simian sarcoma viral (v-sis) oncogene homolog)
4 2.2 0.083
SYK spleen tyrosine kinase 2 -1.1 0.631
TGFA transforming growth factor, alpha 2 -1.0 0.907
TGFBI transforming growth factor, beta-induced, 68kDa 2 2.1 0.164
TP53 tumor protein p53 (Li-Fraumeni syndrome) 4 1.7 0.036
VEGF vascular endothelial growth factor 2 6.6 0.175
G1/S transition of mitotic cell cycle 
(GO:0000082)
CCND1 cyclin D1 (PRAD1: parathyroid adenomatosis 1) 2 -1.3 0.168
insulin-like growth factor binding 
(GO:0005520)
CYR61 cysteine-rich, angiogenic inducer, 61 2 2.9 0.013
KAZALD1 Kazal-type serine protease inhibitor domain 1 2 -1.1 0.770
IGFBP4 insulin-like growth factor binding protein 4 2 1.8 0.002
CTGF connective tissue growth factor 2 2.9 0.006
IGFBP5 insulin-like growth factor binding protein 5 4 2.7 0.041
metalloprotease inhibitor 
(GO:0008191)
TIMP1 tissue inhibitor of metalloproteinase 1 (erythroid 
potentiating activity, collagenase inhibitor)
3 1.4 0.250
methionine adenosyltransferase 
(GO:0004478)
MAT2A methionine adenosyltransferase II, alpha 4 -2.9 0.001
methionine-tRNA ligase 
(GO:0004825)
MARS methionine-tRNA synthetase 2 6.7 0.006Page 9 of 14
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toxicity. More importantly, we were able to show, using
drugs acting on the same pathway, that the inhibitory
effects on cell growth can be potentiated using agents act-
ing on the same pathway. The use of either all-trans-retin-
oic acid (ATRA) or its metabolite 9-cis retinoic acid in this
regard demonstrated similar results, as might be expected.
Furthermore it might be anticipated that these agents
potentiate the effect of fenofibrate via their action on the
PPARα receptor [28]. Similarly, a synergistic effect of RXR
and PPAR agonists has previously been demonstrated in
breast cancer [29] and bladder cancer [30] cell lines. How-
ever, although retinoic acid derivatives alone have been
demonstrated to show activity in breast cancer [31,32]
and other tumours, particularly leukaemias [33,34], there
is limited evidence that retinoids are effective in endome-
trial cancer [15,35]. Indeed, our data suggest that, even at
comparatively high doses of retinoic acid, no inhibition of
Ishikawa cell growth occurs.
The mechanism of action of fenofibrate is, as yet,
unknown. A parallel might be drawn between the effect of
fenofibrate (a PPARα agonist) in endometrial cancer and
thiazolidenediones (TZDs, PPARγ agonists), such as ros-
iglatazone and troglitazone, in breast cancer. TZD's have
been demonstrated to cause inhibition of cancer cell
growth in vitro and/or in vivo in a number of cancers, par-
ticularly breast [29,36], colon [37] and salivary gland
[38]. Although yet to be fully determined, it would appear
that at least one mechanism for this action involves inhi-
bition of translation and transition through G1-S phase of
the cell cycle39. These effects are associated with
decreased expression of D1/E cyclins in the absence of a
change in p21, or cyclin-dependent kinases (CDK's) and
are independent of PPARγ activation [39].
Anti-tumour effects of PPARα-specific agonists appear to
be less commonly reported. One reason for this may be
the perception that PPARα agonists are carcinogenic due
to their tumorigenic effects in rodent liver [14]. Further-
more, agonism of PPARα has been shown to increase pro-
liferation in MCF-7 breast cancer cells [40]. This effect,
however, is reported inconsistently and PPARα agonists
have also demonstrated efficacy in vitro against melanoma
[41] and breast cancer cell lines [42]. These studies outline
various mechanisms which explain the effect of fenofi-
brate on cancer cells. Firstly, PPARα agonist effects on the
cell cycle and apoptosis are mediated by environmental
agents and the MAP kinase pathway [43]. PPAR activity is
also closely linked to the eicosanoid pathway of inflam-
mation and PPARα induces cyclo-oxygenase-2 (PTGS2)
expression, which is linked to the development of colon
cancer [44]. Furthermore, there is significant cross-talk
between PPAR receptors and many other nuclear hor-
mone receptor subfamilies [45-47]. The most obvious of
these is the link to the retinoid receptor family, but even
within this subfamily, sex-steroid hormone influence is
evident. Examples of this are the estrogen-dependence of
Tumour weights in nude mice following endometrial cancer cell xenografting and tr atment with "high se" (0.25%) o"low dose" (0.1%) fenofibratFigure 6
Tumour weights in nude mice following endometrial cancer 
cell xenografting and treatment with "high dose" (0.25%) or 
"low dose" (0.1%) fenofibrate. Top – n = 6 mice per group 
treated for 21 days. Middle – n = 8 mice per group treated 
for 14 days and Bottom – n = 8 mice per group treated for a 
further 10 days with fenofibrate alone. Tumour weights were 
lower in the high-dose fenofibrate-treated mice in the first 
experiment, but this was not repeated in the second experi-
ment.
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mediated anti-inflammatory action stimulated by TNFα is
interrupted by the anti-progesterone RU486 in HUVEC's
[49]. Probably the strongest nuclear hormone interrela-
tionship with the PPAR receptors is to insulin and the IGF-
receptor [47,50,51]. Although the primary clinical func-
tion of TZD's is to increase insulin sensitivity, PPARα ago-
nists also reduce insulin resistance and insulin
concentration in vivo [52]. Furthermore, the strong associ-
ation between PPARs and lipid and glucose homeostasis
appears to be a primary factor in the development of obes-
ity [47,53]. Taken together, these features support the
hypothesis that the PPAR pathway might harbour anti-
neoplastic targets in endometrial cancer, which is known
to be promoted by obesity and hyperinsulinaemia [5].
Indeed, the inhibition of G1-S phase progression, demon-
strated in this study with fenofibrate, is consistent with
the anticipated effects of targeting of PPARα in endome-
trial cancer.
We attempted to demonstrate that the inhibitory effect of
fenofibrate on Ishikawa cell growth was specific for
PPARα. Support for this hypothesis was provided by the
synergistic effects demonstrated from combined treat-
ment with fenofibrate and retinoic acid, and from the lack
of similar effect seen with therapeutic doses of rosiglita-
zone. We have previously demonstrated a functional
PPARα receptor using a luciferase reporter assay [12]. In
this study we also demonstrated absence of mutation
within the coding region of the hPPARα gene in the cell
lines tested, as it is known that up to 15% of endometrial
cancers harbour variants of PPARγ [54].
The gene array experiments were designed to better under-
stand the mechanism of action of this drug, at the tran-
script level. The traditional approach to identification of
differentially expressed genes involves the use of first-
order statistics such as the t-test (eg Cyber-T [55]) or per-
mutation-based methods (eg SAM [56]), often in combi-
nation with a "threshold of interest" applied to fold-
change values in gene expression. Here we have applied
Independent Component Analysis (ICA) [26,57] to iden-
tify a "gene signature" which correlates with our biologi-
cal feature of interest, ie response to high-dose
fenofibrate. Using this method we are not only able to fil-
ter out stochastic noise from the microarray data, but also
to exclude components of the data associated with exper-
imental artefact such as batch effects. Using ICA we could
not discern a gene signature associated with the response
to low-dose (10 µM) fenofibrate, suggesting that the
effects on the transcriptome at this dose were small, con-
sistent with the lack of biological effect seen. Of more
interest, however, was the response to high-dose (100
µM) fenofibrate, which was seen in a significant propor-
tion of the transcriptome (see figure 4). One advantage of
using a factor analysis method is the avoidance of super-
vision bias when identifying differentially expressed
genes. Here we combined ICA with Gene Ontology [58]
analysis to identify groups of genes with shared function
which were differentially expressed with high-dose fenof-
ibrate.
Amongst the identified gene ontology groups, ontologies
related to cell proliferation were over-represented in the
list of differentially expressed genes. These included cell
proliferation, cell growth, cell cycle arrest, and ontologies
related to MAPkinase signalling. Within these functional
groups, genes that were up- or down-regulated were gen-
erally consistent with the experimental findings of inhibi-
tion of G1-S phase progression. Downregulation of Cyclin
D1 (CCND1) was accompanied by upregulation of p8,
p21, GADD45A, GADD45B and TP53. Cyclin D1 is
known to be upregulated in endometrial cancer and is a
common feature of endometrial carcinogenesis [59,60].
Cyclin D1 plays a major role in cell cycle progression and
is therefore central to the proliferative ability of many can-
cers [61]. In view of its importance in cell cycle progres-
sion, we chose Cyclin D1 as one of the genes with which
to verify the array findings and confirmed its downregula-
tion (see figure 4b). Conversely, and as might be expected,
p21 (cyclin-dependent kinase inhibitor 1a, CDKN1A) was
upregulated following administration of high-dose fenof-
ibrate. P8 (COM-1) was also upregulated. P8 encodes for
a protein which inhibits cancer cell growth in estrogen-
dependent breast cancer cell lines [62]. TP53 is another
protein central to the regulation of cancer cell growth [63]
and its gene expression was also upregulated.
Although cell cycle-related genes are important anti-neo-
plastic targets, other pathways are particularly relevant in
endometrial carcinogenesis. There is overwhelming evi-
dence that obesity plays a pathogenetic role in endome-
trial cancer and is most likely mediated by IGF [5,7]. In
particular, the IGF binding proteins appear to play a piv-
otal role in estrogen-dependent endometrial cancer cell
growth [64]. Transcript levels of both IGFBP4 and IGFBP5
as well as Connective Tissue Growth Factor (CTGF,
IGFBP8) were increased in response to fenofibrate, sug-
gesting that this lipid-lowering agent may exert some
direct action on pathways known to be relevant to
endometrial carcinogenesis.
The gene array experiments also revealed a further path-
way which may be involved in the inhibition of Ishikawa
endometrial cancer cell growth. Two of the genes that
were most differentially regulated by fenofibrate were
methionine adenosyltransferase 2-alpha (MAT2A) (FC = -
2.7, p < 0.01) and methionine-tRNA synthetase (FC = 6.7,
p < 0.01). These two genes form part of the methionine
metabolism pathway, central to normal cellular functionPage 11 of 14
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conversion of L-Methionine to S-Adenosyl methionine,
the principal methyl donor. Induction of MAT2A is medi-
ated by TNFα and reduced expression is associated with
inhibition of cell growth [65,66]. Induction of MAT2A has
also been correlated with disease progression in colon
cancer [67]. MAT2A may also prove to be an important
therapeutic target in view of the increasingly realised epi-
genetic role of methylation in endometrial carcinogenesis
[68,69]. By contrast, whether MARS plays a role in car-
cinogenesis is not known, and the induction of this gene
may simply be a reflection of the degree of translational
change taking place under the influence of fenofibrate as
suggested earlier [39].
In addition to gene array analysis, we applied RNA-inter-
ference [70] in order to establish whether the inhibitory
effects of fenofibrate seen were due to activation of the
PPARα receptor. Although our results demonstrated some
diminution of effect at lower doses of fenofibrate, the
main effects were unchanged despite confirmation of at
least 75% knock-down of PPARα expression. A further
unexpected effect encountered during the RNAi experi-
ments was the significant and consistent reduction in cell
viability seen following knock-down of PPAR expression.
This might be explained by the central role PPARα plays
in cellular metabolism and may also account for a blunt-
ing of any direct effect on cell growth induced by PPARα
knock-down.
Furthermore, it was expected that some of the differen-
tially expressed genes identified in the array experiments
would comprise those known to be regulated by fenofi-
brate. Comparison of our gene list to previously pub-
lished data [71,72] failed to demonstrate a similar pattern
of differentially expressed genes, although there were
occasional similarities (eg ↑Stearoyl-CoA desaturase).
One explanation for this may be that the small changes in
metabolic gene expression remained undetectable in an
environment of apoptosis and cell death. A second expla-
nation, however, could be that the majority of published
gene expression data relating to fenofibrate in rodents is
less applicable to human cells.
This latter possibility may also explain the absence of a
consistent demonstrable effect on tumour growth in vivo.
Results from our initial experiment in mice were encour-
aging, but failed to show reduction in tumour growth, or
a difference when retinoic acid was added, in the second
experiment. Furthermore, immunohistochemistry failed
to identify significant levels of PPARα protein expression
in the harvested tumour samples, raising the possibility
that the receptor level is not maintained within the animal
model environment (data not shown). There are known
species differences in the effects of fenofibrate: humans
have a lower level of liver PPARα expression than rodents
[73], the promoter for human Acyl CoA Oxidase is differ-
ent from that in rodents [74] and effects on the cell cycle
in mice liver are different from that in humans [75]. Taken
together, these findings may explain the unexpected
results from our in vivo experiments. A further unexpected
finding from the animal experiments was the increased
tumour size seen in the low dose fenofibrate arm com-
pared to normal diet (p = 0.04). It was postulated that the
serum level of fenofibrate in the low dose arm may have
been well below the anticipated dose, and that a low
fenofibrate dose may have had a stimulatory effect on ISK
cell growth. A further experiment was therefore conducted
to investigate the effect of prolonged (>96 hours) low-
dose (0.1 µM – 3 µM) exposure to fenofibrate, but failed
to show any effect on cell growth (data not shown). The
increased tumour size in this group was therefore consid-
ered to be a statistical, rather than a true biological effect.
A further possibility explaining the absence of expected
effect may have been inadequate dosing, although the
doses chosen were based on previously published data to
achieve desired serum fenofibrate levels [76]. One further
point to note was that the mechanism for delivery of
ATRA ultimately proved to be a problem resulting in tox-
icity, either due to the dose (although this was well within
established dosage according to the manufacturer) or to
local reaction to the pellet. Our preference would have
been to use Liposomal ATRA (ATRA-iv, Antigenics Inc,
New York) but it proved impossible to obtain this from
the manufacturer. It is possible that the toxicity encoun-
tered from the pellets prevented a demonstrable response
to fenofibrate in the final experiment.
PPARγ agonists have been demonstrated to show tumour
inhibition in vitro and in vivo, in a number of tumour
types such as breast and colon. PPARα agonists, however,
have so far failed to show similar results, despite inhibi-
tory effects on tumour growth in breast cancer [42] and
melanoma [41] in vitro. It is highly plausible that the spe-
cies differences in PPARα activity [72,77] is at least in part
responsible for the difficulties in demonstrating efficacy
of PPARα agonists in a rodent model of human tumours.
The promising effects of these agents in vitro, however,
suggest that the lack of a consistent effect on endometrial
cancer in mice warrants further investigation, most likely
requiring the use of an alternative animal model.
The full mechanism of action of fenofibrate remains to be
clarified but it appears to exert effects on cell cycle regula-
tors in addition to pathways pertinent to endometrial car-
cinogenesis. The data presented suggest that PPARα
remains a potential therapeutic target in endometrial can-
cer, whilst the addition of retinoic acid to fenofibrate cre-
ates a potent therapeutic combination in vitro. The
development of an appropriate animal model, however,Page 12 of 14
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Molecular Cancer 2006, 5:13 http://www.molecular-cancer.com/content/5/1/13remains essential to demonstrating the applicability of
this promising combination in the treatment of endome-
trial cancer.
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